onychomycosis

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole.

Amorolfine hydrochloride (Amorolfine HCl) is an antifungal reagent. It exerts the antifungal activity by selectively interrupting two steps in the pathway of ergosterol synthesis and eventually disrupting the function and structure of fungal cell membrane. Amorolfine hydrochloride , a morpholine antifungal drug, can inhibit D14 reductase and D7-D8 isomerase. These enzymes can deplete ergosterol and cause ignosterol to accumulate in the fungal cytoplasmic cell membranes.

Efinaconazole (KP-103)(KP-103) is an Azole Antifungal currently under development as a topical treatment for onychomycosis.

ME1111, a succinate dehydrogenase inhibitor of Trichophyton species, serves as an antifungal agent effective against dermatophytes. Notably proficient in penetrating human nails, it is utilized in onychomycosis research.

Chlorfenson is used to treat onychomycosis as the primary indication.

(Z)-Lanoconazole is the Z configuration of Lanoconazole, used for investigating dermatophytosis and onychomycosis. It inhibits sterol 14-alpha demethylase, disrupting fungal membrane ergosterol biosynthesis. Lanoconazole is a potent, orally active imidazole antifungal agent with a broad spectrum of activity against fungi both in vitro and in vivo [1] [2].